MAINZ BIOMED B.V. MYNZ 深 滬
等待開盤 11-17 09:30:00 美东时间
1.43
-0.030
-2.05%
華盛通- 最 高1.58
- 今 開1.45
- 成交量 96.37万股
- 最 低 1.38
- 昨 收 1.46
- 總市值 972.41万
- 52周最高 10.556
- 市盈率 靜 --
- 換手率 14.17%
- 52周最低 1.21
- 委 比 -25.56%
- 總股本 680.01万
- 歷史最高 1200.00
- 量 比 0.37
- 振 幅 13.70%
- 歷史最低 1.21
- 每 手 1
- 風險率 2.17%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Mersana Therapeutics (NASDAQ:MRSN) stock increased by 208.1% to $27.33...
11-13 20:06
Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025
Mainz Biomed, a molecular genetics diagnostic company, will participate in MEDICA 2025, a leading global healthcare trade show in Düsseldorf, Germany. The Company will showcase its ColoAlert®, a non-invasive test for early colorectal cancer detection, and other diagnostic solutions. MEDICA attracts thousands of exhibitors and visitors, fostering innovation and collaboration in healthcare. Mainz Biomed aims to strengthen partnerships and raise awa...
11-12 13:01
Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS)
Mainz Biomed N.V. will participate in the 38th Annual GARPS conference in Germany to strengthen connections with gastroenterology experts, discuss cancer prevention, and showcase its ColoAlert® colorectal cancer detection product. The event offers opportunities for collaboration and education on early cancer detection. More information is available on the company’s website or via LinkedIn, X, and Facebook.
11-10 13:01
Mainz Biomed to Attend 2025 Maxim Growth Summit
Mainz Biomed, a molecular genetics diagnostic company focused on early cancer detection, announced its participation in the 2025 Maxim Growth Summit, scheduled for October 22-23 at The Hard Rock Hotel NYC. The prestigious event will gather industry leaders, innovators, and institutions to discuss latest trends across multiple sectors, featuring keynote speakers Larry Kudlow and Christopher Ruddy, and roundtable discussions with CEOs from small an...
10-15 13:01
Mainz Biomed to Present the Future of Colorectal Cancer Screening at WEO CRC Screening Committee Meeting
Mainz Biomed will participate in the World Endoscopy Organization's CRC Screening Committee meeting on October 3, 2025, in Berlin. Dr. Lena Krammes will present findings from the eAArly DETECT study, highlighting RNA-based stool testing's potential in early CRC detection and prevention. The test showed 97% sensitivity and specificity for CRC, 82% for advanced adenomas, and 100% for those with high-grade dysplasia. Mainz Biomed emphasizes its comm...
09-30 12:01
Mainz Biomed Launches ColoAlert Colorectal Cancer Test In Switzerland
Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce the commercial launch of its flagship
09-23 20:08
Mainz Biomed Announces Commercial Launch of ColoAlert® in Switzerland
Mainz Biomed announced the commercial launch of its colorectal cancer screening product, ColoAlert®, in Switzerland. Key achievements include a partnership with labor team, regulatory approval from Swissmedic, and successful technology transfer enabling local processing. The company is also progressing its eAArly DETECT study, aiming to complete enrollment by year-end 2025.
09-23 12:01
Mainz Biomed's ColoAlert Receives MHRA Approval For Colorectal Cancer Screening In The UK
Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announces today that ColoAlert® has received official
09-02 20:11
Mainz Biomed Announces Registration of ColoAlert in the United Kingdom
Mainz Biomed's ColoAlert®, a non-invasive DNA-based colorectal cancer screening test, has been officially registered with the UK's MHRA and authorized for marketing. This milestone, achieved through a partnership with EDX Medical Group, aims to increase accessibility and participation in CRC screening, addressing the UK's fourth most common cancer. ColoAlert detects DNA biomarkers in stool samples, complementing existing screening programs and of...
09-02 12:01
Mainz Biomed's ColoAlert Receives Swissmedic Approval, Paving Way For Swiss Launch Of Non-Invasive Colorectal Cancer Test
Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announces today that ColoAlert®, its non-invasive colorectal
08-13 20:18
